|Articles|September 1, 2011

Applied Clinical Trials

  • Applied Clinical Trials-09-01-2011
  • Volume 20
  • Issue 9

Most Protocols Require Multiple Amendments

A recent study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) found that more than half of all protocols require one or more amendments.

A recent study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) found that more than half of all protocols require one or more amendments. Based on data from 3,410 protocols provided by 17 large and midsize pharmaceutical and biotechnology companies, Tufts CSDD found that completed protocols across all phases had an average of 2.5 amendments requiring 6.9 changes to the protocol per amendment. Later-stage Phase II and III protocols had a higher average number of amendments, 2.7 and 3.5 respectively. The most commonly cited causes of amendments included the availability of new safety information, requests from regulatory agencies to amend the study, and changes in the study strategy. Protocol design flaws and difficulties recruiting study volunteers were also cited as top causes. The study found that the incidence of amendments is associated with protocol complexity and duration. The mean number of amendments per protocol, for example, was positively and significantly correlated (p<.001) with the number of procedures per protocol, study length, and the number of investigative sites conducting that protocol.

—Tufts Center for the Study of Drug Development, http://csdd.tufts.edu.

Mean number of amendments per protocol. (Source: Tufts Center for the Study of Drug Development)

Articles in this issue

about 15 years ago

Recruitment Roles

about 15 years ago

Clusters' Last Stand?

about 15 years ago

Lost to Follow-Up Survey Results

about 15 years ago

Sneak Peak at FDA Guidance

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.